| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
This deficiency will be considered by the Hearings Panel (the "Panel") at a hearing that has been scheduled for April 25, 2024 (the "Hearing") to address the Company's other current deficiencies.
As previously reported on May 8, 2023, due to the resignation of one of the Company's board members from its Board of Directors and therefore its Audit Committee on April 12, 2023, the Company no longer complied with the Audit Committee Requirements. Pursuant to Listing Rule 5605(c)(4), Nasdaq provided the Company a cure period to regain compliance with the Audit Committee Requirements, which ended on April 12, 2024.
Posted In: BRSH
